Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses
- PMID: 9541583
- DOI: 10.1002/(SICI)1521-4141(199803)28:03<881::AID-IMMU881>3.0.CO;2-0
Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses
Abstract
Our present study provides evidence that the 4-1BB signal is critical to CD28 co-stimulation in maintaining T cell activation when CD28 has been down-regulated because of repeated stimulation. The 4-1BB signal synergized with CD28 co-stimulation by lowering the threshold of anti-CD28 required to sustain proliferation and IL-2 production. The 4-1BB signal also modulated CD28-mediated cytokine profiles by markedly enhancing Th1 but suppressing Th2-type cytokine production. The 4-1BB signal generated Th1-type cells, as identified by intracellular IFN-gamma production. IFN-gamma induction was detected preferentially in 4-1BB-expressing cells, but not in those expressing CD30. 4-1BB and CD30 were induced in both CD4+ and CD8+ cells, but the location of the two molecules was mutually exclusive in each T cell subset. Our study suggests that the 4-1BB signal regulates CD28 co-stimulation in the targeted subset cells to favor Th1 development and maintain long-term cell growth.
Similar articles
-
Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.J Immunol. 1997 Apr 1;158(7):3081-9. J Immunol. 1997. PMID: 9120260
-
Role of 4-1BB (CD137) in the functional activation of cord blood CD28(-)CD8(+) T cells.Blood. 2002 Nov 1;100(9):3253-60. doi: 10.1182/blood-2001-11-0136. Blood. 2002. PMID: 12384425
-
Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response.J Immunol. 2000 Dec 1;165(11):6193-204. doi: 10.4049/jimmunol.165.11.6193. J Immunol. 2000. PMID: 11086053
-
Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
-
Role of 4-1BB:4-1BB ligand in cancer immunotherapy.Cancer Gene Ther. 2004 Mar;11(3):215-26. doi: 10.1038/sj.cgt.7700670. Cancer Gene Ther. 2004. PMID: 14671675 Review.
Cited by
-
Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.Front Immunol. 2022 Sep 8;13:993624. doi: 10.3389/fimmu.2022.993624. eCollection 2022. Front Immunol. 2022. PMID: 36159809 Free PMC article. Review.
-
Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma.Int J Biol Sci. 2013;9(2):134-41. doi: 10.7150/ijbs.4891. Epub 2013 Jan 16. Int J Biol Sci. 2013. PMID: 23411595 Free PMC article.
-
The nature of activatory and tolerogenic dendritic cell-derived signal II.Front Immunol. 2013 Feb 28;4:53. doi: 10.3389/fimmu.2013.00053. eCollection 2013. Front Immunol. 2013. PMID: 23450201 Free PMC article.
-
Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.J Immunother. 2013 May;36(4):248-57. doi: 10.1097/CJI.0b013e3182943549. J Immunother. 2013. PMID: 23603859 Free PMC article.
-
Therapeutic vaccination with tumor cells that engage CD137.J Mol Med (Berl). 2003 Feb;81(2):71-86. doi: 10.1007/s00109-002-0413-8. Epub 2003 Feb 8. J Mol Med (Berl). 2003. PMID: 12601523 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials